- Catalyst Biosciences Completes Merger with Targacept and Creates a Protease-Based Hemostasis and Anti-Complement Company – click to read
- Catalyst Biosciences Announces Positive Results from a Phase 1 Clinical Trial of its Next Generation Coagulation Factor VIIa in Patients with Hemophilia A or B and Preclinical Results from its Factor IX and Factor Xa Programs – click to read
- Catalyst Biosciences Announces Multiple Data Presentations at the 2015 International Society on Thrombosis and Haemostasis Meeting – click to read
Next Generation Hemostasis Product Candidates
Our most advanced program is focused on the treatment of hemophilia and surgical bleeding using our potent, long acting variants of proteases that promote blood clotting.
Anti- Complement Product Research
Our second area of focus is regulation of the complement cascade, a series of molecular processes that plays a central role in the body’s inflammatory and immune responses.
The Catalyst Advantage
Drug candidates for severe medical conditions
Learn more about the medicines we are developing.
Our unique and proprietary science
Understand our science.
Addressing diseases with unmet medical needs
Share our passion about treating disease.
We have an experienced and passionate team
Learn more about the Catalyst team and mission/culture.